TLRY Stock Overview
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tilray Brands, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$5.12 |
| 52 Week Low | US$1.82 |
| Beta | 2.42 |
| 1 Month Change | -14.68% |
| 3 Month Change | -34.04% |
| 1 Year Change | -59.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.45% |
Recent News & Updates
Recent updates
Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues
Apr 17
An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 28% Undervalued
Feb 03Tilray Brands, Inc.'s (NASDAQ:TLRY) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 09Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review
Oct 06Japan should permit medical cannabis, health ministry panel says
Sep 29Most Canadian cannabis LPs not following Aurora's decline after earnings disappointment
Sep 21Tilray's Canadian cannabis brand RIFF launches Drumsticks
Sep 15Tilray: Hype Train Crashed
Sep 08Tilray Brands: No One Is Happy
Sep 01Tilray gets non-profit NHSF nod for use of CBD100 in trials in Australia, New Zealand
Aug 23Tilray gets approval in Poland to commercialize medical cannabis products
Aug 17Tilray Brands inks CBD beverage distribution deal with Southern Glazer’s
Aug 03Will Tilray Q4 result bring earnings surprise?
Jul 27With Tilray's $155M investment in HEXO, Roth Capital sees cannabis headwinds and softness
Jul 15Tilray's Good Supply brand expands product offering in Québec
Jul 06Tilray Medical expands portfolio of medical cannabis products in the United Kingdom
Jun 29Tilray Stock: Don't Even Think About It
Jun 16Tilray Brands: Almost Good Enough
May 17Tilray Short Interest Hits New High
May 11Robust Earnings May Not Tell The Whole Story For Tilray Brands (NASDAQ:TLRY)
Apr 14Tilray Reports Positive Earnings: Look Beyond The Headline Numbers
Apr 07Decriminalization Buzz is Moving Tilray (NASDAQ:TLRY), but The Company may have some Significant Issues
Mar 25Tilray: Keeping Competition Alive
Mar 25Tilray Brands: The Big Money Is Still In The US
Feb 11Quick Take On Tilray's Recent Disappointing Earnings
Jan 24Tilray's (NASDAQ:TLRY) Earnings Need a Scratch Below the Surface
Jan 12Tilray: Sell Dead Cat Bounce
Jan 10Tilray: $4 Billion Market Opportunity In German Adult Recreational Cannabis
Dec 03Calculating The Fair Value Of Tilray, Inc. (NASDAQ:TLRY)
Nov 12Is Tilray Stock A Buy, Sell, Or Hold After Recent Earnings?
Oct 27Is Tilray Stock Overvalued Or Undervalued? Still Overvalued Now, But Looking Cheap Enough
Oct 18Tilray, Inc. (NASDAQ:TLRY) May be Risky for Institutions but Good for Traders
Oct 08Tilray: Out Of Touch
Oct 07Shareholder Returns
| TLRY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -22.8% | -2.9% | 0.3% |
| 1Y | -59.1% | -4.9% | -0.7% |
Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: TLRY underperformed the US Market which returned -0.7% over the past year.
Price Volatility
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: TLRY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1,700 | Irwin Simon | https://www.tilray.com |
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.
Tilray Brands, Inc. Fundamentals Summary
| TLRY fundamental statistics | |
|---|---|
| Market Cap | US$1.15b |
| Earnings (TTM) | -US$1.79b |
| Revenue (TTM) | US$596.26m |
1.9x
P/S Ratio-0.6x
P/E RatioIs TLRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLRY income statement (TTM) | |
|---|---|
| Revenue | US$596.26m |
| Cost of Revenue | US$519.97m |
| Gross Profit | US$76.29m |
| Other Expenses | US$1.87b |
| Earnings | -US$1.79b |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | 12.79% |
| Net Profit Margin | -300.55% |
| Debt/Equity Ratio | 17.4% |
How did TLRY perform over the long term?
See historical performance and comparison